Related Experiment Video
Updated: Apr 30, 2026
Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
Geniposide attenuates oligomeric Aβ(1-42)-induced inflammatory response by targeting RAGE-dependent signaling in BV2
1C Building, Beijing Normal University Science Park, No. 12, Xueyuan Southern Street, Haidian District, Beijing, P.R.China, 100088. zws@bnu.edu.cn.
Abstract:
The neuroinflammation induced by amyloid-β (Aβ) is one of the key events in Alzheimer's disease (AD) progress in which microglia are the main cells involved. Receptor for advanced glycation end products (RAGE) mediates and enhances Aβ-induced microglial activation and leads to induction of proinflammatory mediators, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). Geniposide, a pharmacologically active component purified from gardenia fruit, exhibits a broad spectrum anti-inflammatory effect as well as neurotrophic and neuroprotective properties. However, the effects of geniposide on Aβ-mediated microglial pathways have not been fully discovered. Here, we demonstrate that geniposide treatment significantly blocks Aβ-induced RAGE-dependent signaling (activation of ERK and NF-κB) along with the production of TNF-α and IL-1β in cultured BV2 microglia cells. Notably, based on the data from coimmunoprecipitation assay, we infer that geniposide exerts protective effects on Aβ-induced inflammatroy response through blocking Aβ binding to RAGE and suppressing the RAGE-mediated signaling pathway. Taken together, these findings indicate that geniposide is a potent suppressor of neuroflammation through inhibiting RAGE-dependent signaling pathway. Thus, geniposide may be a potential therapeutic agent for the treatment of neuroinflammation that is involved in neurological diseases such as AD.
Insights
Geniposide effectively reduces neuroinflammation by blocking amyloid-beta
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Neuroinflammation, driven by amyloid-beta (Aβ) and mediated by microglia, is central to Alzheimer's disease (AD) pathogenesis.
- Receptor for advanced glycation end products (RAGE) amplifies Aβ-induced microglial activation, promoting pro-inflammatory cytokine release.
Purpose of the Study:
- To investigate the impact of geniposide on Aβ-mediated microglial activation pathways.
- To determine if geniposide can inhibit RAGE-dependent signaling and neuroinflammation.
Main Methods:
- Utilized cultured BV2 microglia cells exposed to Aβ.
- Administered geniposide and assessed its effects on RAGE signaling (ERK, NF-κB activation).
- Measured pro-inflammatory mediator production (TNF-α, IL-1β) and analyzed Aβ-RAGE binding via coimmunoprecipitation.
Main Results:
- Geniposide significantly inhibited Aβ-induced RAGE-dependent signaling, including ERK and NF-κB activation.
- Geniposide suppressed the production of TNF-α and IL-1β in microglia.
- Evidence suggests geniposide blocks Aβ binding to RAGE, thereby mitigating inflammatory responses.
Conclusions:
- Geniposide is a potent suppressor of neuroinflammation by inhibiting the RAGE-dependent signaling pathway.
- Geniposide demonstrates potential as a therapeutic agent for neuroinflammatory conditions like Alzheimer's disease.
